<DOC>
	<DOCNO>NCT00891670</DOCNO>
	<brief_summary>The purpose study determine impact adjunctive cilostazol platelet inhibition carrier non-carriers loss-of-function CYP2C19 allele .</brief_summary>
	<brief_title>Comparison Platelet Inhibition With Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel According Hepatic Cytochrome 2C19 Allele ( CYP2C19 ) Polymorphism</brief_title>
	<detailed_description>The additional platelet inhibition clopidogrel , thienopyridine inhibitor platelet P2Y12 adenosine diphosphate ( ADP ) receptor , reduce risk ischemic event coronary stent implantation . Because inter-individual variability platelet response clopidogrel , significant proportion suboptimal platelet inhibition report . In addition , persistent residual platelet reactivity measure platelet function test show association cardiovascular outcomes percutaneous coronary intervention ( PCI ) . Various clinical factor genetic polymorphism study predict degree antiplatelet response clopidogrel . Interestingly , recent study find carrier loss-of-function hepatic cytochrome ( CYP ) 2C19 allele significantly low level active metabolite clopidogrel , diminish platelet inhibition , high rate major adverse cardiovascular event non-carriers , set PCI acute coronary syndrome ( ACS ) . These finding raise need solution overcome enhance post-clopidogrel platelet reactivity influence loss-of-function CYP2C19 allele . Increasing dose clopidogrel new potent P2Y12 antagonist ( prasugrel ) may alternative antiplatelet regimen patient loss-of-function CYP variant . Cilostazol reversibly induce platelet inhibition via blockade phosphodiesterase ( PDE ) type 3 catalyse mainly CYP3A . A recent study demonstrate adjunctive cilostazol dual antiplatelet therapy ( triple antiplatelet therapy ) intensify platelet inhibition compare high maintenance-dose ( MD ) 150 mg/day . Therefore , triple antiplatelet therapy could also alternative antiplatelet therapy improve platelet inhibition clinical outcome carrier CYP2C19 mutant allele .</detailed_description>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>1 . The patient must least 18 year age 2 . Significant coronary artery stenosis ( &gt; 70 % visual estimate ) 3 . Elective coronary stent implantation 1 . Acute myocardial infarction 2 . Hemodynamic instability active bleeding bleeding diatheses 3 . Oral anticoagulation therapy warfarin , use periprocedural glycoprotein IIb/IIIa inhibitor 4 . Contraindication antiplatelet therapy 5 . Left ventricular ejection fraction &lt; 30 % 6 . Leukocyte count &lt; 3,000/mm3 , platelet count &lt; 100,000/mm3 7 . AST ALT ≥ 3 time upper normal 8 . Serum creatinine level ≥ 2.5 mg/dL 9. stroke within 3 month 10 . Noncardiac disease life expectancy &lt; 1 year 11 . Inability follow protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>CYP2C19 polymorphism</keyword>
	<keyword>platelet</keyword>
	<keyword>Adjunctive cilostazol</keyword>
	<keyword>high maintenance dose clopidogrel</keyword>
	<keyword>P2Y12 Reaction Unit</keyword>
</DOC>